ࡱ> :<9 bjbjWW :==xx$jwyyyyyy$b #tww{&Rc0,x#x#x#x#x : <
> Re: Expedited appeal of denial of coverage for <> (DOB: xxx, SSN: xxxxxxx, Tel: xxxxx) UHC #: xxx Group#: xxx Company: xxx Service Ref #: xxx Additional information: Prescribing physician: Dr. xxxxxxxx (NPI####) Facility tax ID: ### (Facility name) Medication: Rituximab (J 9310) Indication: Refractory sclerotic chronic graft versus host disease following allogeneic hematopoietic cell transplantation <> To Whom It May Concern: I am writing this letter on behalf of my patient, xxxx (DOB: xxxx, ID: xxxx, Group# xxxx), to request coverage for rituximab for the treatment of steroid-refractory, sclerotic chronic graft versus host disease. <> is a x y/o woman..give clinical history. Rituximab is considered one of the standard treatments for steroid-refractory chronic GVHD (Cutler et al, Blood 2006, Zaja et al, BMT 2007, Kharfan-Dabaja et al, BBMT 2009, plus many other studies), and I have recommended that she receive treatment with this medication. I appreciate your time and consideration of this matter and do hope that you will allow <> to be treated with rituximab. Please expedite your evaluation so that the patient may begin therapy as soon as possible as her sclerosis is progressing rapidly. If you would like to discuss this case directly, please call me at xxx-xxx-xxxx. The best way to reach me otherwise is via email (xxxxxxxxxx) and we can set up a time to talk if necessary. Thank you for your help, <> Attachments: Cutler C et al, Blood 2006; 108: 756-762. Rituximab for steroid-refractory chronic graft-versus-host disease. Zaja F et al. BMT 2007; 40: 273-277. Treatment of refractory chronic GVHD with rituximab: a GITMO study Kharfan-Dabaja MA et al. BBMT 2009; 15: 1005-1013. Efficacy of rituximab in the setting of steroid-refractory chronic GVHD: a systematic review and meta-analysis.   ?JMNTW^elqsz{~Խ{d{M{M{M{-hzh 8vCJOJ^JaJfHq -hzh)CJOJ^JaJfHq 'h^CJOJ^JaJfHq -hzhk_CJOJ^JaJfHq -hzh{)CJOJ^JaJfHq -hzh uCJOJ^JaJfHq -hzhsmCJOJ^JaJfHq 'hT*LCJOJ^JaJfHq  Ls @  /p@ P !$`'gd) ^`gdT*Lgd^ gd)gd)    ֲ}f\OBOhzhOJQJ^Jhzh{)OJQJ^JhxOJQJ^J,hzh{)OJQJ]^JfHq )hzh^OJQJ^JfHq hxhT*Lh^h^OJQJ^Jh{)OJQJ^J#hT*LOJQJ^JfHq #hxOJQJ^JfHq #h:q OJQJ^JfHq -hzh?CJOJ^JaJfHq     # ) - 6 : ; @ G H ^ t I f |  @ d  J ܸܸܴo]#h%OJQJ^JfHq #h^OJQJ^JfHq #hT*LOJQJ^JfHq )h^h^OJQJ^JfHq h%hsmhT*Lh^hQsOJQJ^Jhzhl]OJQJ^Jhzh 8vOJQJ^Jhzh{)OJQJ^JhzhOJQJ^JhT*LOJQJ^J"   w & Fgdx & Fgd^ /p@ P !$`'gd) /p@ P !$`'gd^gd^J V p { 3uwcۤۙ~hxh^CJaJhxCJaJhsmCJaJhsmhsmCJaJh}:^h^mH sH  h}:^h^hLh^mHsHhzh6OJQJ^Jhzh{)OJQJ^Jh^hT*LOJQJ^Jh^h^OJQJ^JhxOJQJ^J8P:p{)/ =!"#F$% Dp^ 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH @`@ NormalCJ_HaJmH sH tH DA D Default Paragraph FontViV  Table Normal :V 44 la (k (No List ZoZ G[Normal] 7$8$H$$CJOJQJ^J_HaJmH sH tH e@  GHTML Preformatted7 2( Px 4 #\'*.25@9B*CJOJPJ^JaJphP P  Balloon TextCJOJQJaJmHsHtHJ/!J Balloon Text CharCJOJQJaJB' 1B V45Comment ReferenceCJaJ<B< V45 Comment TextCJaJ@jAB@ V45Comment Subject5\6U a6 ^ Hyperlink >*B*ph6B@r6 sm Body TextCJaJ44 smBody Text CharPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]   J    8@0(  B S  ?^elq#)-6:fj|RV 3w  33333 ??JJTTWW^^eellqqJV ??JJTTWW^^eellqqJV @j88^8`OJPJQJ^Jo(-^`OJQJ^Jo(hHopp^p`OJQJo(hH@ @ ^@ `OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hH^`OJQJ^Jo(hHoPP^P`OJQJo(hH Z[         ! u:q k_g}&)V45 83<?hAT*Ll]smQs 8vzn|\6@ u{)&s#w%d^x$@X@Unknown G*Ax Times New Roman5Symbol3. *Cx ArialI. ??Arial Unicode MScLucida GrandeTimes New RomanG5  jMS Mincho-3 fg?= *Cx Courier New;WingdingsA$BCambria Math"qh&'#(''d d !F243QHX ? G2!xxAttn: __________________jmayordnelson Oh+'0  0 < H T`hpxAttn: __________________jmayorNormaldnelson4Microsoft Office Word@@@\{8~@bd՜.+,0 hp   Seattle Cancer Care Alliance  Attn: __________________ Title  !"#$%&'(*+,-./02345678;Root Entry FpR+=Data 1Table#WordDocument:SummaryInformation()DocumentSummaryInformation81CompObjy  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q